Ferring Pharmaceuticals, Inc. Release: In Patients With Active, Left-Sided Ulcerative Colitis, Study Shows Once-Daily Dose of Mesalazine Granules Provided Similar Results to Twice-Daily Dose

VIENNA--(BUSINESS WIRE)--Results of a recent sub analysis1 of data from the MOTUS study2 presented today at the Congress of European Crohn’s and Colitis Organisation showed that a once-daily 4g dose of mesalazine (Pentasa® granules) was non-inferior to the twice-daily 2g dose for such formulation in inducing remission in patients with left-sided active ulcerative colitis. The objective of the MOTUS study was to show non-inferiority of once-daily mesalazine versus twice-daily dosing for the induction of remission in active ulcerative colitis. As many patients with ulcerative colitis experience left-sided disease, the aim of the new sub analysis was to assess specifically the efficacy in patients with left-sided ulcerative colitis.